Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Valutazione di efficacia di un antiangiogenetico (Bevacizumab)
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
[31] Paridaens R, Biganzoli L, Br<strong>un</strong>ing P,et al. Paclitaxel versua Doxorubicin as first line single- agent for<br />
metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized<br />
Study with cross-over. J Clin Oncol 2000; 18:724-733.<br />
[32] Sledge GW, Neuberg D, Bernardo P et al.Phase III trial of Doxorubicin, paclitaxel and the combination of<br />
doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial<br />
(E1193). J Clin Oncol 2003; 21:588-592.<br />
[33] Nabholtz JM, Senn HI, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin<br />
plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-<br />
containig chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413-12 -1424<br />
[34] Sjostrom J , Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-<br />
fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study<br />
with cross-over on progression by the Scan<strong>di</strong>navian Breast Group. Eur J Cancer 1999 ; 35 :1194 -1201<br />
[35] Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast<br />
cancer after anthracycline therapy failure. Br J Cancer 2002; 87:1210-1215.<br />
[36] Icli E, Akbulut H et al. Paclitaxel(T) vs Cisplatin +VP16 (EP) in metastatic breast cancer treated with<br />
anthracyclines: a phase III randomized study. Turkish Oncology Group. Ann Oncol 2002; 13 (Suppl 5):47.<br />
[37] Ch<strong>un</strong>g C, Carlson R. Goals and objectives in the management of metastatic breast cancer. Oncologist<br />
2003; 8:514-20<br />
[38] Carlson RW, Anderson BO, Bensinger W et al. The NCCN breast cancer clinical practice guidelines in<br />
oncology. J NCCN 2003; 1:148-188<br />
[39] Coates AS, Stockler M, Wilcken N. Controversies in metastatic breast cancer ; optimal duration of<br />
chemotherapy. ASCO Educational Handbook 2003:119-121.<br />
[40] Baselga J. Herceptin Alone or in combination with chemotherapy in the treatment of HER 2 positive<br />
metastatic breast cancer: pivotal trials.Oncology 2001; 61: 14-21<br />
[41] Hanahan D, Weinberg R, : The hallmarks of cancer. Cell 100: 57-70,2000 A<br />
[42] Ji WR et al. Characterization ok kringle domains of angiostatin as antagonists of endothelial cell<br />
migration, an important process in angiogenesis.FASEB J 1998; 12:1731-8<br />
Maria Pittalis<br />
<strong>Valutazione</strong> <strong>di</strong> <strong>efficacia</strong> <strong>di</strong> <strong>un</strong> <strong>antiangiogenetico</strong> (<strong>Bevacizumab</strong>) associata a chemioterapia in pazienti con carcinoma<br />
della mammella metastatico<br />
Tesi <strong>di</strong> dottorato in scienze Biome<strong>di</strong>che-Epidemiologia molecolare dei tumori<br />
Università degli Stu<strong>di</strong> <strong>di</strong> Sassari<br />
83
Change language